Winchester D P, Jeske J M, Goldschmidt R A
Northwestern University Medical School, Evanston, IL, USA.
CA Cancer J Clin. 2000 May-Jun;50(3):184-200. doi: 10.3322/canjclin.50.3.184.
The widespread utilization of screening mammography has produced a shift in the stage of breast cancer at diagnosis in the US: Currently, 12% to 15% of newly diagnosed breast cancer cases annually are ductal carcinoma in-situ (DCIS). The diagnosis is made, in at least 90% of patients, with mammography. Only about 10% of patients will have a palpable mass. The accurate characterization and visualization of calcifications typically requires magnification of mammographic imaging. The morphology of the calcifications is generally considered to be the most important factor in differentiating benign from malignant formations. Round and uniform shapes are more likely to be benign, while linear and heterogeneous morphologies are associated with DCIS. Following a complete mammographic work-up, most suspicious lesions are potential candidates for a stereotactic core needle biopsy. Ten percent to 50% of patients initially diagnosed with atypical ductal hyperplasia by needle biopsy have subsequently been surgically diagnosed with cancer near the biopsy site. Due to this relatively high incidence of co-existent carcinoma, a needle biopsy diagnosis of atypical ductal hyperplasia necessitates subsequent surgical excision. The most important change in our thinking about DCIS was from a monolithic view, conceiving of DCIS as a single disease highly likely to invade if left untreated, to the realization that DCIS represents a non-obligate precursor with a variable risk of progression, depending on a combination of factors, such as histology, lesion, size, and margin status. In discussing treatment options, patients should understand that local recurrence following total mastectomy is rare and that this is the procedure of choice for disease that cannot be adequately encompassed with a breast-conserving approach. If the patient and her surgeon are in agreement about proceeding with a breast-conserving approach, there needs to be a clear understanding of the incidence and implications of local recurrence. In all such discussions with newly diagnosed patients, however, it is essential to emphasize the excellent prognosis with this disease, irrespective of the surgical approach.
目前,每年新诊断的乳腺癌病例中有12%至15%为导管原位癌(DCIS)。至少90%的患者是通过乳腺钼靶检查确诊的。只有约10%的患者可触及肿块。钙化的准确特征描述和可视化通常需要乳腺钼靶成像的放大。钙化的形态一般被认为是区分良性与恶性病变的最重要因素。圆形且均匀的形态更可能是良性的,而线性和不均匀形态则与DCIS相关。在完成全面的乳腺钼靶检查后,大多数可疑病变是立体定向空心针活检的潜在对象。最初通过针吸活检诊断为非典型导管增生的患者中,有10%至50%随后在活检部位附近被手术诊断为癌症。由于这种并存癌的发生率相对较高,针吸活检诊断为非典型导管增生后需要进行后续手术切除。我们对DCIS认识上最重要的转变是,从将DCIS视为一种单一疾病,若不治疗极有可能侵袭,转变为认识到DCIS是一种非必然的癌前病变,其进展风险各异,取决于组织学、病变大小和边缘状态等多种因素的综合作用。在讨论治疗方案时,患者应明白全乳切除术后局部复发很少见,这是无法采用保乳方法充分治疗的疾病的首选手术方式。如果患者及其外科医生一致同意采用保乳方法,就需要清楚了解局部复发的发生率及其影响。然而,在与新诊断患者的所有此类讨论中至关重要的是,无论采用何种手术方式,都要强调这种疾病的预后良好。